Latest Albany Molecular Research Inc. Stories
Approval to Handle Schedule 2 and 2N Controlled Substances at this location Further Supports AMRI SMARTSOURCING(TM) Offering ALBANY, N.Y., June 18, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that its Burlington, Mass., site has received approval to expand its current U.S. Drug Enforcement Administration (DEA) registration to handle Schedule 2 and 2N controlled substances. The license represents the DEA's acknowledgement of Burlington's physical security and quality...
ALBANY, N.Y., June 17, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Susan Collins has been promoted to Director of Business Development for North American Discovery Services, reporting to Christopher Conway, Vice President, Business Development. In this new role, Ms. Collins is responsible for leading AMRI's North American Discovery Business Development team in the promotion of the full spectrum of AMRI's global drug discovery services. Bringing 19 years of...
ALBANY, N.Y., June 12, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Thomas E. D'Ambra, Ph.D., President and Chief Executive Officer at AMRI, will present at the 2013 Wells Fargo Securities Healthcare Conference on Wednesday, June 19, 2013 at 10:40 a.m. ET. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) About AMRI Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated...
ALBANY, N.Y., June 5, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI), a leading global contract research and manufacturing organization, has announced that the Board of Directors has unanimously voted to separate the role of Chairman and Chief Executive Officer and has named William S. Marth, an active member of the AMRI Board of Directors, as Chairman of the Board, effective June 5, 2013. The position of Chairman has been held by Thomas E. D'Ambra, Ph.D. since the Company's founding....
ALBANY, N.Y., May 30, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Thomas E. D'Ambra, Ph.D., Chairman, President and Chief Executive Officer at AMRI, will present at the Jefferies 2013 Global Healthcare Conference on Thursday, June 6, 2013 at 11:30 a.m. ET. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) An audio webcast of the corporate presentation will be available to investors and interested parties by accessing the company's website at...
ALBANY, N.Y., May 15, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Michael M. Nolan, Vice President, Chief Financial Officer and Treasurer at AMRI, will present at the UBS Global Healthcare Conference on Wednesday, May 22, 2013 at 9:00 a.m. ET. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO) An audio webcast of the corporate presentation will be available to investors and interested parties by accessing the company's website at www.amriglobal.com....
Total First Quarter Revenue up 11% at $59.4 Million and Adjusted EPS increased to $0.23 ALBANY, N.Y., May 7, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the first quarter ended March 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO) Financial highlights for the first quarter include: Adjusted diluted earnings per share of $0.23, an increase of $0.21 from the prior-year period Contract revenue of $46.5...
ALBANY, N.Y., April 24, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced it will issue first quarter financial results before the opening of the market on Tuesday, May 7, 2013. Following the release of its results, the company will host a conference call and simultaneous webcast at 10 a.m. ET. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) The conference call can be accessed by dialing 888-556-4997 (domestic calls) or 719-325-2452 (international calls) at...
New Agreement Extends Drug Discovery and Development Collaboration Between the Companies ALBANY, N.Y., April 23, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that it has entered into a new five-year service agreement with Ono Pharmaceutical Company, Ltd., (TSE: 4528), a pharmaceutical company headquartered in Osaka, Japan. Under the terms of the agreement, AMRI may provide a range of services from early drug discovery to cGMP manufacturing. (Logo:...
ALBANY, N.Y., April 23, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that AMRI Chairman, President and Chief Executive Officer Thomas E. D'Ambra, Ph.D. will present at the 12(th) Annual Needham Healthcare Conference on Tuesday, April 30, 2013 at 12:50 p.m. ET. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) A webcast of the corporate presentation will be available to investors and interested parties by accessing the company's website at...
